Group 1 - The company, along with several partners, has established a partnership agreement to form a new enterprise with an initial investment of RMB 227.27 million [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership will prioritize investments in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership will enable deep participation in the research and development of innovative drug pipelines, allowing the company to standardize and modularize its digital pharmaceutical R&D solutions [2] - The partnership will hold pipeline rights and participate in early clinical trials, aiming to capture key segments of the industry value chain while avoiding the complexities and long-term risks associated with traditional equity investments [2] - The company anticipates efficient exits through the transfer or sale of pipeline rights, facilitating rapid capital turnover and value realization [2]

Group 1 - The core point of the news is that Taimei Medical Technology (02576.HK) has established a partnership agreement to form a partnership enterprise focused on equity investment in innovative drug companies [1][2] - The total initial investment amount from all partners in the partnership enterprise is RMB 227.27 million, with specific contributions from each partner [1] - The business scope of the partnership includes investing in innovative drug companies, specifically targeting those in the early to growth stages of drug development, subject to approval by relevant Chinese government authorities [1] Group 2 - The board believes that by establishing the partnership enterprise, the company can deeply engage in the research and development of innovative drug pipelines, standardizing and modularizing its digital pharmaceutical R&D solutions for early to growth stage companies [2] - The partnership allows the company to hold pipeline rights and participate in early clinical trials, thereby capturing key segments of the industry value chain while avoiding the complexities and long-term risks associated with traditional equity investments [2] - The strategy aims for efficient exits through the transfer or sale of pipelines, facilitating rapid capital turnover and value realization [2]